skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 
Home » Regular Columns » Three Quick Facts » Three Quick Facts: WizzAir, Oncimmune Holdings and 88Energy

Three things you need to know in the financial markets this morning from investment writer, Tony Cross.


Comparatively slim pickings as we emerge from the long Easter weekend but discount airline WizzAir [LON:WIZZ] has this morning published its latest traffic figures covering March. Passenger numbers remain hobbled by the COVID pandemic despite the airline appearing to have run one of the most comprehensive networks in Europe over the last 12 months. Expansion plans also continue unabated, but with capacity down 60% from March 2020 and passenger numbers off almost three quarters, it lays bare the challenges faced by the sector as a whole. That said, liquidity detailed on Q3 results published at the end of January suggested the airline could withstand more turbulence for a while, yet.

Oncimmune Holdings

AIM listed biotech Oncimmune Holdings [LON:ONC] has this morning announced two separate agreements, one with Roche and the other with Cedars-Sinai Medical Centre. Both are for the use of the company’s newly developed “infections disease panel” which will help with the diagnosis and treatment of COVID-19 patients. This provides further support for the company’s innovations in the space, but to what extent these developments have already been priced in remains to be seen.

Subscribe for more stories like this, 8am weekdays - for free!


Sticking with AIM, there’s an operations update out from 88Energy [LON:88E]. We’ve seen a number of these from the business in recent weeks which have typically served to buoy the share price even when the news has looked less than stellar. The tone of today’s note again could have the potential to disappoint – will investors who have seen the share price rise eight fold in less than a month find sufficient inspiration here to not be tempted by profit taking?

Sign up for three quick facts and more with our Free Daily Digest newsletter, every weekday morning.

This article is not investment advice. Investors should do their own research or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we follow most closely. They represent significant growth stories in our view. Our in-depth reports detail why we like them.


Subscribe for more stories like this, 8am weekdays - for free!

Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top